Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

NCT04549025 is registered in ClinicalTrials.gov with Jounce Therapeutics, Inc. as lead sponsor.

NCT NCT04549025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04549025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
Lead sponsor
Jounce Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 19, 2020
Completion date
April 25, 2024
Enrollment
69 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc